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Pertussis, or whooping cough, is a highly contagious respiratory disease that is caused by the Gram-negative bacterium
Bordetella pertussis, which is transmitted exclusively from human to human. While vaccination against B. pertussis has been
successful, replacement of the whole cell vaccine with an acellular component vaccine has correlated with reemergence of
the disease, especially in adolescents and infants. Based on their presumed importance in mediating adherence to host
tissues, filamentous hemagglutinin (FHA) and fimbria (FIM) were selected as components of most acellular pertussis
vaccines. In this review, we describe the biogenesis of FHA and FIM, recent data that show that these factors do, in fact,
play critical roles in adherence to respiratory epithelium, and evidence that they also contribute to persistence in the lower
respiratory tract by modulating the host immune response. We also discuss shortcomings of whole cell and acellular
pertussis vaccines and the possibility that FHA and FIM could serve as effective protective antigens in next-generation
vaccines.
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INTRODUCTION
Pertussis (aka whooping cough) is caused by the fastidious
Gram-negative bacterium Bordetella pertussis (Melvin et al. 2014).
This highly contagious respiratory disease is most severe in in-
fants and young children. Pertussis was widespread until the
late 1940s, with annual case rates as high as 270 000 in the
United States and fatality rates at about 10% (Clark 2014). Whole
cell vaccines (wP), composed of killed B. pertussis organisms and
introduced in the late 1940s, were hugely successful and mor-
bidity andmortality rates plummeted throughout the 1950s and
1960s in areas with high vaccine coverage (Clark 2014). Adverse
publicity in the 1970s, however, led to decreased compliance
andprompted the development of acellular component vaccines
(aP) that are composed of one to five purified pertussis proteins
[chemically inactivated pertussis toxin (PT), filamentous hemag-
glutinin (FHA), pertactin (PRN), and/or fimbriae of serotype 2 or
3 (FIM2, FIM3)]. aP vaccines were introduced in the 1990s and
are the only pertussis vaccines currently licensed in the USA
and most other developed countries. Coincident with the tran-
sition to the aP vaccines, case rates and regional pertussis epi-
demics have increased steadily, with pertussis disease incidence
in 2012 reaching a level last seen in the 1950s (Clark 2014). Re-
cent disease rates have increased most dramatically in adoles-
cents and epidemiological studies indicate that immunity from
aP vaccines is not as durable as initially thought (Klein et al. 2012;
Misegades et al. 2012; Witt, Katz and Witt 2012; Tartof et al. 2013;
Koepke et al. 2014; McGirr and Fisman 2015). Consequently, there
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Figure 1. FHA biogenesis. FhaB is an ∼370 kDa polypeptide. After removal of the 71 aa signal sequence, the TPS domain of FhaB (gold) interacts with the POTRA domains
of FhaC (blue), initiating translocation across the outermembrane (om). The N-terminal ∼2500 aa of FhaB fold into a β-helix on the cell surface. The C-terminal proline-
rich region (PRR) may interact with a periplasmic protein or protein domain, and the extreme C-terminal domain (ECT) inhibits an unknown protease. The N-terminus
of the prodomain (PNT, dark green) prevents translocation of the prodomain across the om. In response to an unknown signal, the ECT releases inhibition of the
unknown protease and the prodomain is degraded. FhaB is also processed by the serine protease SphB1 (purple) to form ‘mature’ ∼240 kDa FHA. FHA is released from
the cell surface by an unknown mechanism.
is renewed interest in understanding molecular mechanisms
of pertussis pathogenesis and the immune response that is
generated upon natural infection with the goal of developing a
new generation of safe yet effective pertussis vaccines.
Two B. pertussis surface structures that have featured promi-
nently in the development of pertussis vaccines are FHA and
FIM. Both were identified initially as hemagglutinins or agglu-
tinogens responsible for determining the serotype of B. pertussis
strains. Agglutinogens 2 and 3 were subsequently determined to
be pili or fimbriae (FIM2 and FIM3) and FHA was determined to
be a large non-fimbrial filamentous hemagglutinating molecule
(Ashworth, Irons and Dowsett 2006). Despite little supportive
data at the time, both FHA and FIM were presumed to mediate
adherence of B. pertussis to host tissues and therefore there was
an effort to ensure that wP vaccines were made from B. pertussis
strains producing both FIM2 and FIM3 (as well as FHA) and that
aP vaccines included these antigens. In this review, we discuss
current knowledge of the function of FHA and FIM in the ability
of B. pertussis to establish respiratory infection and to influence
the development of immunity and considerations for the devel-
opment of new pertussis vaccines. Although most studies have
been conducted using B. pertussis or proteins derived from B.
pertussis, the human-restricted host range of this organism has
hampered studies aimed at determining the roles of specific vir-
ulence factors in disease pathogenesis and the induction of im-
munity. Several groups have therefore included B. bronchiseptica
in their analyses because this extremely closely related organ-
ism naturally infects nearly all mammals and therefore patho-
genesis can be investigated in the context of a natural bacteria–
host interaction. Our review will therefore also summarize data
obtained from studies with B. bronchiseptica.
FHA AND FIM BIOGENESIS
Electron microscopy and structural analyses indicate that FHA,
which is both cell associated and released into culture super-
natants, is an ∼4 × 40 nm β-helix with a globular domain at
one end and a molecular mass of ∼240 kDa (Makhov et al. 1994;
Kajava et al. 2001). FHA is exported to the cell surface by the two-
partner secretion (TPS) pathway. TPS is a broadly used mecha-
nism by which Gram-negative bacteria export large, β-helical,
exoproteins to the cell surface using outer membrane, channel-
forming, β-barrel proteins and FHA and its cognate outer mem-
brane transporter protein, FhaC, are its prototypical members
(Mazar and Cotter 2007; Jacob-Dubuisson et al. 2013). FHA is first
synthesized as an ∼375 kDa preproprotein called FhaB (Fig. 1). It
is translocated across the cytoplasmicmembrane by the general
Sec system via a signal sequence that contains an extended sig-
nal peptide region (ESPR) at its N-terminus (Chevalier et al. 2004).
ESPRs are present onmany TPS exoproteins and autotransporter
proteins and although they appear to be important for con-
trolled secretion of these large proteins, their exact function is
unclear (Desvaux et al. 2006, 2007). After removal of the ESPR-
containing signal sequence, the N-terminal ∼250 aa ‘TPS do-
main’ of FhaB initiates export across the outer membrane by in-
teracting with the periplasmically located polypeptide transport








Figure 2. FIM biogenesis. The FimC protein is predicted to be an integral outer membrane (om) β-barrel usher protein. FimB is predicted to function as a chaperone
that binds FimD, Fim2 and Fim3 proteins, preventing their degradation in the periplasm and directing them to FimC for translocation across the om. Within FimC, the
FimB chaperone transfers the fimbrial subunit to the next subunit in the channel by donor strand exchange, resulting in elongation of the FIM structure.
associated (POTRA) domains of FhaC (Hodak et al. 2006; Delat-
tre et al. 2011; Baud et al. 2014). Export of FhaB proceeds in
an N- to C-terminal direction, with the N-terminus remaining
associated with FhaC such that a hairpin structure forms and
elongates on the cell surface (Mazar and Cotter 2006). All TPS
exoproteins are predicted to contain large β-helical regions, es-
pecially near their N-termini, and it has been postulated that
folding of the stable β-helix facilitates export by contributing
to a Brownian ratchet mechanism (Jacob-Dubuisson et al. 2013).
Once approximately 2500 aa of FhaB have been exported to the
surface, a region called the prodomain N-terminus (PNT) pre-
vents further translocation and hence the C-terminal ∼1200 aa
of FhaB (called the prodomain) remains in the periplasm (Noël
et al. 2012). Specific subdomains within the prodomain are im-
portant for preventing degradation by an unknown protease, in-
fluencing the folding of the C-terminal domain of mature FHA
(called the MCD) on the cell surface, and contributing somehow
to resistance to phagocytic cell clearance (Noël et al. 2012; Melvin
et al. 2015) (discussed below). Degradation of the prodomain in
the periplasm and cleavage N-terminal to the prodomain by the
surface-localized autotransporter SphB1 results in the forma-
tion of the mature ∼240 kDa FHA molecule that is oriented with
its C-terminus (the MCD) located distally from the cell surface
(Coutte et al. 2001;Mazar and Cotter 2006). A substantial amount
of FHA is ultimately released from the cell. Neither the mecha-
nism of FHA release nor whether FHA release is important for
infection is known.
Bordetella FIM are members of the type 1 pili family. These
long, thin, hair-like structures are composed of thousands of
pilin subunits. The structures are ∼7.5 nm in diameter and can
be several hundred nanometers in length (Heck, Trus and Steven
1996). Type I pili are exported by the chaperone–usher mecha-
nism, which has been extensively studied in uropathogenic Es-
cherichia coli (UPEC) (see Busch, Phan andWaksman 2015 for a re-
view). Based on aa sequence similarity, the Bordetella FimB, FimC
and FimD proteins are hypothesized to function as the periplas-
mic chaperone, the outer membrane usher and the tip adhesin,
respectively (Willems, van der Heide and Mooi 1992). The ma-
jor pilins in Bordetella are Fim2 and Fim3. Other major pilins
(FimX, FimN and FimA) are also encoded by most strains, but
their production has not been detected. According to the current
model based on UPEC pili (Busch, Phan andWaksman 2015), the
pilin, chaperone and usher proteins are translocated across the
cytoplasmic membrane by the Sec system. The pilin subunits
bind to the chaperone, FimB in Bordetella, by a mechanism called
donor strand complementation in which an N-terminal exten-
sion (Nte) region of the pilin fits within a groove in the chaper-
one to complete an immunoglobulin-like domain. The chaper-
one delivers the pilin subunits to the usher, where donor strand
exchange (transfer of the Nte of the pilin from the chaperone
to another pilin protein) and translocation of a growing chain of
pilin subunits across the outer membrane occur (Fig. 2). The he-
lical nature of the pilus rod is thought to contribute to the ability
of the pili to withstand shear forces while maintaining adhesion
because although it is rigid, it can uncoil under stress, acting like
a spring or shock absorber (Thanassi, Bliska and Christie 2012).
This feature would likely be important during adherence of Bor-
detella to beating cilia in the trachea and bronchi.
Genes encoding the exoproteins and outer membrane trans-
porters of most TPS systems are adjacent and cotranscribed
(Jacob-Dubuisson et al. 2013). Similarly, genes required for type
1 pili biogenesis are typically clustered and coregulated (Busch,
Phan and Waksman 2015). In Bordetella, however, the fimA, fimB,
fimC and fimD genes are located between fhaB and fhaC (Fig. 3).
Moreover, fimD and fhaC overlap such that they are both tran-
scriptionally and translationally coupled. A single promoter 5′
to the fimB gene appears to be responsible for transcription
of the fimBCDfhaC operon (Willems, van der Heide and Mooi
1992). While the fimA gene is intact in B. bronchiseptica (and B.
parapertussis) strains, it is missing its 5′ end and promoter re-
gion in B. pertussis strains (Fig. 3 and Boschwitz et al. 1997). Al-
though fimA is predicted to encode a major pilin subunit, FimA-
containing FIM have not been described. All B. pertussis and
B. bronchiseptica strains that have been characterized produce
FIM composed of Fim2, Fim3 or both, the structural genes for
which are located elsewhere on the chromosome. The fhaB-fimA-
fimBCDfhaC gene cluster is adjacent to and divergent from the
bvgAS operon, which encodes the BvgAS two-component reg-
ulatory system that activates transcription of all known pro-
tein virulence factor-encoding genes (Cotter and DiRita 2000;
Cummings et al. 2006). When the BvgAS system is active (such as
when the bacteria are within the mammalian respiratory tract;
Cotter and Miller 1994; Merkel et al. 1998), BvgA is phosphory-
lated and activates transcription of the fhaB and fimB promot-
ers, as well as the bvgAS P1 promoter, by binding high-affinity
binding sites (Boucher et al. 1997, 2003; Cotter and Jones 2003).
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Figure 3. The bvgAS-fhaB-fimA-fimBCDfhaC gene cluster. The arrangement of the bvgAS-fhaB-fimA-fimBCDfhaC genes on the chromosome is shown. The pointed end of
the box for each gene represents the 3′ end. Promoters are shown as arrows.
Transcription of the fim2 and fim3 genes is also activated by Bv-
gAS (Chen et al. 2010). Hence, FHA and FIM are amongst the first
virulence factors produced when the bacteria move from Bvg−
phase conditions (ex vivo) to Bvg+ phase conditions (in vivo). The
fact that the bvgAS, fhaB and fimBCDfhaC genes are clustered and
coregulated suggests that they play similarly important and per-
haps codependent or coordinated roles during infection.
FHA AND FIM FUNCTION
The locus responsible for FHA production was first identified in
1983 as the site of a Tn5 transposon in a B. pertussis mutant
that was unable to agglutinate sheep erythrocytes (Weiss et al.
1983). Comparison of this strain, or strains containing deletion
mutations in fhaB, with wild-type B. pertussis for their ability to
adhere to ciliated epithelium (Relman et al. 1989; Prasad et al.
1993), non-ciliated epithelium (van den Berg et al. 1999), Chinese
hamster ovary cells (Relman et al. 1989; Aricò et al. 1993), mono-
cytes (Relman et al. 1989; Prasad et al. 1993; Ishibashi, Claus and
Relman 1994) and neutrophils (Mobberley-Schuman and Weiss
2005) suggested that FHA plays an important role in mediating
adherence of the bacteria to host cells. Similarly, studies with
strains containing either a large deletion mutation in fhaB or
in which the fhaB and fhaC genes were expressed in a bvgS
mutant indicated that FHA is both necessary and sufficient
for B. bronchiseptica to adhere to a variety of cells lines in vitro
(Cotter et al. 1998;Mattoo,Miller and Cotter 2000). Although early
preparations of anti-FHA antibodies often contained antibodies
against other Bordetella factors, blocking studies also implicated
FHA as an important adhesin in vitro (Sato et al. 1981; Redhead
1985; Prasad et al. 1993; van den Berg et al. 1999; Julio et al. 2009).
Analyses aimed at identifying domains within FHA that me-
diate interactions with host cells initially implicated a region
near the N-terminus of FHA (named the heparin-binding do-
main, HBD) in binding sulfated carbohydrates such as hep-
arin and haparan sulfate and in agglutinating sheep erythro-
cytes. This region contains consensus heparin-binding sites of
fibronectin (Cardin et al. 1991; Busby et al. 1995) and FHA purified
from culture supernatants was shown to interact with heparin-
sepharose (Menozzi et al. 1994). Moreover, incubation with hep-
arin decreased B. pertussis adherence to HeLa cells (Menozzi et al.
1994). However, the current model for FHA secretion places the
HBD near the bacterial surface where it would likely be inac-
cessible to host cell molecules (Mazar and Cotter 2006; Noël
et al. 2012), casting doubt aboutwhether these interactions occur
in vivo. Residues 1141–1279 were named the carbohydrate recog-
nition domain because a monoclonal antibody that recognized
an epitope in this region blocked the binding of FHA to glycol-
ipids and reduced binding of B. pertussis to rabbit ciliated ep-
ithelial cells, which could also be blocked by glycolipids (Tuo-
manen et al. 1988; Prasad et al. 1993). A polyclonal antibody
raised against a polypeptide containing this region did not, how-
ever, block binding of B. pertussis or B. bronchiseptica to either
rat lung epithelial (L2) cells or J774A.1 macrophage-like cells
(Julio et al. 2009). FHA also contains an RGD triplet centered
at aa 1098 (numbering based on FHA from B. pertussis) which
was implicated in adherence to monocytes (Relman et al. 1990;
Aricò et al. 1993; Ishibashi, Claus and Relman 1994) by interact-
ing with leukocyte response integrin-integrin associated protein
(LRI-IAP) complexes and inducing surface presentation of CR3
(aka CD11b/CD18) (Ishibashi, Claus and Relman 1994). However,
a B. bronchiseptica strain producing FHA with RAE in place of
RGD was indistinguishable from wild-type bacteria in its abil-
ity to establish persistent infection in rats and mice (Julio et al.
2009). Focus on the N-terminal regions of FHA was due in part
to the assumption that FHA was oriented with its N-terminus
extended distally from the cell surface. Secretion and topology
studies in 2006 (Mazar and Cotter 2006), however, showed that
the N-terminus remains anchored at the cell surface and the C-
terminus of mature FHA (the MCD) is located distally, placing it
in an optimal location to interactwith host cells. Antibody block-
ing studies and mutational analyses demonstrated the impor-
tance of the MCD in binding to epithelial cells and macrophages
in vitro and for FHA function in vivo (Julio et al. 2009), and there-
fore it seems likely that FHA mediates interactions with host
cells during infection primarily via the MCD, although roles for
other regions of FHA have not been definitively ruled out. Iden-
tifying the molecule(s) with which FHA interacts in vivo remains
an important and elusive goal.
Although fimbriae have been shown to function as impor-
tant adhesins for many bacterial pathogens, evidence for FIM
mediated-adherence in Bordetella has been lacking. Several stud-
ies investigating the role of FIM in B. pertussiswere conducted in
the 1990s (Hazenbos et al. 1994, 1995; Geuijen et al. 1997), but
all of the strains used in these experiments were also defec-
tive for FHA production and hence conclusions about the role
of FIM could not be drawn. Rodriguez et al. (2006) reported that
anti-FIM antibodies could block attachment of B. pertussis to ep-
ithelial cells, but FIM-deficient bacteria were not included in the
analysis as a control. A B. bronchiseptica strain lacking FIM due
to an in-frame deletion mutation of the fimBCD genes but unal-
tered for FHA production was indistinguishable from wild-type
bacteria in its ability to adhere to a broad range of cell lines
in vitro, providing evidence against a role for FIM in adherence
(Mattoo, Miller and Cotter 2000). However, this strain was defec-
tive in adherence to ciliated rabbit tracheal explants, suggesting
that FIM may mediate adherence specifically to cilia (Edwards,
Groathouse and Boitano 2005). Given the lack of evidence for
FIM-mediated adherence in vitro, it is not surprising that a host
cell receptor has not been identified. While studies using puri-
fied fimbrial subunits suggested that FIM may interact with sul-
fated sugars (Geuijen et al. 1998), confirmatory experiments with
intact fimbriae have not been reported.
To avoid caveats associated with working with cultured cell
lines in vitro and to investigate the role of FIM and FHA in adher-
ence to respiratory epithelium in a biologically relevant context,
we recently developed an in vivo adherence assay using B. bron-
chiseptica andmice (Scheller et al. 2015).We inoculatedmicewith
50 μl of PBS containing 7.5 × 104 cfu of wild-type or mutant bac-
teria, performed bronchoalveolar lavage (BAL) 30 minutes later,
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and determined the number of CFU recovered in the BAL fluid
and retained in the lungs post-BAL. These experiments revealed
equally critical roles for FHA and FIM in adherence to tissue
within the lower respiratory tract; neither factor could medi-
ate adherence without the other as the fhaB and fimBCD mu-
tants were as defective as each other, as a fhaBfimBCD dou-
ble mutant, and as a bvgS mutant in this assay. Determining
where wild-type, fhaB and fimBCD, mutants localized within
the lungs when not removed by BAL provided additional insight
into FHAand FIM function. FHA-deficient bacteria, likewild-type
bacteria, localized to major airways (bronchi and bronchioles),
while FIM-deficient bacteria localized predominantly to alveoli.
These data suggest that FIM mediates adherence specifically to
ciliated epithelium (without FIM, the inoculated bacteria bypass
the bronchi and bronchioles and reach the alveoli), but that this
adherence alone is not sufficient to resist removal by BAL. Simi-
larly, FHA-mediated adherence in the alveoli either does not oc-
cur or is insufficiently strong to resist BAL. Hence, we propose a
model in which FIM adhere specifically, but with low or moder-
ate affinity, to cilia, bringing the bacteria close enough for FHA to
bind to these cells with high affinity that is sufficient for the bac-
teria to resist BAL in our experiments andmucociliary clearance
during infection.
Roles for FIM and FHA in adherence to ciliated epithelium
in the lower respiratory tract are consistent with the data ob-
tained from inoculating rats and pigs intranasally with a small
volume of PBS containing a relatively small number of bacteria.
In these natural-host colonization models, FHA-deficient and
FIM-deficient B. bronchiseptica are recovered only from the nasal
cavity (the initial site of inoculation), while wild-type bacteria
colonize the nasal cavity initially, then the trachea within about
5 days and they persist in both the nasal cavity and the lower
respiratory tract (predominantly the trachea) indefinitely (Cotter
et al. 1998; Mattoo, Miller and Cotter 2000; Nicholson, Brockmeier
and Loving 2009). Experiments with high-dose, large-volume-
inoculation mouse models suggest that FIM and FHA perform
functions beyond simplymediating adherence to host cells. Both
fhaB andfimBCDmutants induce amore robust inflammatory
response, characterized by high levels of the proinflammatory
cytokine interleukin (IL)-1β, and the neutrophil andmacrophage
chemokines KC andMCP-1, respectively, in the lungs at 1–3 days
post-inoculation compared with wild-type bacteria (Henderson
et al. 2012; Scheller et al. 2015). Examination of hematoxylin and
eosin-stained lung sections reveal correspondingly increased in-
flammatory cell infiltrate in the lungs of mice inoculated with
the mutants compared with those from mice inoculated with
wild-type bacteria. In addition, the fhaB and fimBCD mu-
tants are cleared from the lungswithin 2weeks post-inoculation
while wild-type bacteria typically persist for a month or more in
this model. These data suggest that FIM and FHA are required
for wild-type B. bronchiseptica to suppress the initial inflamma-
tory response to infection and that doing so facilitates their per-
sistence. Coinoculation experiments suggest that in addition to
influencing the intensity of the inflammatory response that de-
velops, FHA and FIM also contribute to the ability of B. bron-
chiseptica to defend itself from clearance by the elicited innate
immune response (Inatsuka, Julio and Cotter 2005; Henderson
et al. 2012; Scheller et al. 2015). When wild-type and fhaB bac-
teria were coinoculated into mice, the level of proinflammatory
cytokines and chemokines present in the lungs 1–3 days post-
inoculation was similar to that of mice inoculated with only
wild-type bacteria, suggesting that the wild-type bacteria sup-
pressed the overall inflammatory response. However, although
the fhaB mutant persisted longer in the coinoculation experi-
ment thanwhen inoculated alone, it was still cleared faster than
the coinoculated wild-type bacteria, suggesting that it is defec-
tive at defending itself against clearance by the recruited phago-
cytic cells or other components of the early immune response.
Coinoculation of wild-type and FIM-deficient bacteria also re-
sulted in proinflammatory cytokine and chemokine levels sim-
ilar to those induced by wild-type bacteria, but the persistence
defect of the fimBCD strain was as severe as when inoculated
alone. Considering the results of the bacterial localization stud-
ies, these data suggest that complementation by wild-type bac-
teria requires close proximity; wild-type bacteria could ‘rescue’
the FHA mutant because they also localize to major airways
while wild-type bacteria were unable to rescue FIM mutants
because the FIM mutants localize to alveoli.
Most recently, we found evidence that it is full-length FhaB,
rather than mature ∼240 kDa FHA, that is important for me-
diating resistance to clearance by the elicited inflammatory re-
sponse (Melvin et al. 2015). We constructed and characterized B.
bronchiseptica strains that produce FhaB proteins lacking either
the PRR, the ECT or both of these domains that are located at the
end of the full-length FhaB protein (Fig. 1). The PRR strain was
indistinguishable from wild-type bacteria in its ability to pro-
duce full-length FhaB (aside from the FhaB protein missing its
PRR domain in the mutant), to process FhaB to FHA and to re-
lease FHA into culture supernatants in vitro. ThePRR strainwas
also indistinguishable from wild-type bacteria in its ability to
mediate adherence to cell lines in vitro and to respiratory epithe-
lium in vivo and it suppressed the initial inflammatory response
to infection similarly to wild-type bacteria. The PRR mutant
was defective, however, in its ability to persist in the lower res-
piratory tract; it was cleared from the lungs of mice as quickly
as the fhaB strain. Because this mutant produces mature FHA
that is indistinguishable from that produced by wild-type bacte-
ria in our assays, and because the FhaB prodomain is degraded
rapidly and does not exist as a stand-alone polypeptide, these re-
sults implicate a role for full-length FhaB in persistence, specif-
ically in resistance to clearance by the early immune response.
We hypothesize that the PRR domain is involved in delivering
a toxin (perhaps adenylate cyclase toxin) to phagocytic inflam-
matory cells in response to binding that is mediated by the MCD
region of full-length FhaB.
Overall, data from comparing wild-type and mutant B. bron-
chiseptica strains in natural-host animalmodels support amodel
in which wild-type bacteria use FIM for initial adherence to cili-
ated epithelial cells in the lower respiratory tract and then FHA
for tight adherence to these cells. Colonization of the respira-
tory epithelium induces inflammation, likely due to recognition
of LPS and other MAMPs on, or released by, the bacteria by TLRs
on host cells, resulting in the production of proinflammatory cy-
tokines and chemokines. Neutrophils, macrophages, dendritic
cells and lymphocytes are then recruited to the site of infection
and as these cells attempt to clear the bacteria, theymay also re-
lease cytokines and chemokines, amplifying the inflammatory
response. Wild-type B. bronchiseptica (and likely also B. pertussis)
suppress the inflammatory response in a manner dependent on
FIM and FHA, but whether they do so through interactions with
epithelial cells, inflammatory cells or both and the mechanisms
involved are unknown. Wild-type bacteria, in a manner depen-
dent on the PRR of FhaB, also appear to be capable, to some ex-
tent, of resisting clearance by recruited phagocytic cells, which
contributes to bacterial persistence in the lower respiratory tract
(Melvin et al. 2015). The bacteria are ultimately cleared, how-
ever, in a manner dependent on the adaptive immune response
(Harvill et al. 1999).
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FHA AND FIM: PROTECTIVE ANTIGENS?
Antibodies were initially thought to be of prime importance for
protection against pertussis. Consequently, with the rationale
that antibodies against adhesinswould block colonization, there
was an effort to use B. pertussis strains producing both FIM2 and
FIM3 in the production of whole cell vaccines and when acel-
lular vaccines were developed, FIM and FHA were considered
to be important, if not essential, components. However, the aP
and wP vaccines induce serum antibody responses to vaccine
components that are similar in magnitude to those induced by
infection, yet human case control and cohort studies indicate
that immunity induced by aP vaccination is not as durable as
immunity induced by wP vaccination, which is not as durable as
immunity induced by infection with B. pertussis, (Plotkin 2013;
Edwards and Berbers 2014; Acosta et al. 2015). Moreover, sero-
logical correlates of protection were never established in clini-
cal vaccine trials. Attention has therefore turned to understand-
ing the role of cell-mediated immunity in controlling pertussis.
These studies have shown that immunization with aP vaccines
induces primarily a Th2 or mixed Th1/Th2 response, while im-
munization with wP vaccines and infection with B. pertussis in-
duce primarily a Th1 response (Zepp et al. 1996; Ausiello et al.
1997, 1999; He et al. 1998; Ryan et al. 1998; Edwards and Berbers
2014). The hypothesis that a Th1, and possibly a Th17, type cell-
mediated immune response is required for protection from per-
tussis is also supported by data from mouse studies (Mills et al.
1993; Barbic et al. 1997; Leef et al. 2000; Ross et al. 2013). Because
most of the human studies were conducted before the appreci-
ation of Th17 cells, the induction of this T-cell subpopulation in
response to wP vaccination or B. pertussis infection in humans
is unknown. Recent studies, however, attempted but failed to
detect B. pertussis antigen-specific Th17 cells in children immu-
nized with aP vaccines, supporting the conclusion that aP vac-
cines induce exclusively Th2 or Th1/Th2 responses (Stenger et al.
2010; Schure et al. 2012, 2013) and strengthening the hypothesis
that cell-mediated immunity, and not antibodies, is essential for
protection.
Insight into the specific contributions of types of immune re-
sponses induced by vaccination versus infection has come from
studies using the recently developed baboonmodel. Thismodel,
using Papio anubis, accurately recapitulates many features of hu-
man pertussis, including paroxysmal cough, lymphocytosis and
aerosol transmission (Warfel, Beren and Merkel 2012a,b). Ba-
boons infected with B. pertussis developed strong, long-lasting
Th1 andTh17 responses (Warfel et al. 2012b;Warfel, Zimmerman
and Merkel 2014). After recovery from the initial infection, the
baboons were completely protected from both disease (cough
and lymphocytosis) and colonization upon challenge with B. per-
tussis. Baboons immunized with wP (in the form of DTwP) also
developed both Th1 and Th17 responses, although they were
not as strong as those induced in response to infection (Warfel,
Zimmerman and Merkel 2014). DTwP-vaccinated baboons were
protected from disease, but not from colonization, although
they cleared infection in about half the time as naı̈ve animals
(∼2 weeks versus 1 month). Baboons immunized with DTaP de-
veloped a mixed Th1/Th2 response. They were also protected
from disease, but not colonization; in fact, they cleared infection
as slowly as naı̈ve animals. Most importantly and perhaps re-
vealing with regard to the current reemergence of pertussis, ba-
boons immunized with DTaP and then challenged were capable
of transmitting infection to naı̈ve animals. All baboons thatwere
either infected with B. pertussis or immunized with wP or aP vac-
cines generated high titers of serum anti-Bordetella antibodies,
demonstrating that, consistent with the studies on humans, dif-
ferences in serum antibody titer do not account for differences
in protection. Warfel and colleagues concluded from the baboon
(and human) studies that antibodies may mediate protection
against disease while Th1 and Th17 type cell-mediated immune
responses mediate protection against colonization (Warfel,
Zimmerman and Merkel 2014; Warfel and Edwards 2015). While
this explanation is plausible, it does not fully account for the fact
that baboons that had been infected previously were completely
protected from colonization while baboons vaccinated with wP
vaccines were not, yet both had generated Th1 and Th17 re-
sponses. It is possible that the difference in protection fromcolo-
nization in convalescent andwP-vaccinated animals stems from
differences in the magnitude of the Th1 and Th17 responses in-
duced, or differences in the specific antigens to which these re-
sponseswere directed. However, another possibility that has not
been investigated is that protection from colonization is medi-
ated by mucosal IgA antibodies and that parenteral immuniza-
tion with either aP or wP vaccines fails to generate a sufficiently
strong mucosal antibody response to afford this protection. Our
recent data demonstrating the essentiality of FHA and FIM for
adherence to respiratory epithelium suggest that mucosal an-
tibodies against either or both of these factors would block ad-
herence and therefore protect against colonization and, conse-
quently, disease. In support of this hypothesis, two studies using
an intranasal inoculation protocol have shown that FHA could
induce a protective immune response inmice (Alonso et al. 2002;
Knight et al. 2006). We therefore believe that efforts towards de-
veloping safe and efficacious pertussis vaccines should include
obtaining a complete understanding of the immune responses
that are induced by natural infection as well as those induced
by wP and aP vaccines for comparison and that these studies
should include measurements of mucosal IgA levels. A finding
that mucosal antibodies to FHA and /or FIM are sufficient for
protection against colonization would have a dramatic impact
on vaccine development as effort could be focused on inducing
this specific type of response, perhaps even focused on specific
domains of FHA and FIM.
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Melvin JA, Scheller EV, Noël CR, et al. New insight into filamen-
tous hemagglutinin secretion reveals a role for full-length
FhaB in Bordetella virulence. mBio 2015;6:e01189–15.
Menozzi FD, Boucher PE, Riveau G, et al. Surface-associated fila-
mentous hemagglutinin induces autoagglutination of Borde-
tella pertussis. Infect Immun 1994;62:4261–9.
Merkel TJ, Stibitz S, Keith JM, et al. Contribution of regulation
by the bvg locus to respiratory infection of mice by Bordetella
pertussis. Infect Immun 1998;66:4367–73.
Mills KH, Barnard A, Watkins J, et al. Cell-mediated immunity
to Bordetella pertussis: role of Th1 cells in bacterial clear-
ance in a murine respiratory infection model. Infect Immun
1993;61:399–410.
Misegades LK, Winter K, Harriman K, et al. Association of child-
hood pertussis with receipt of 5 doses of pertussis vac-
cine by time since last vaccine dose, California, 2010. JAMA
2012;308:2126–32.
Mobberley-Schuman PS, Weiss AA. Influence of CR3
(CD11b/CD18) expression on phagocytosis of Bordetella
pertussis by human neutrophils. Infect Immun 2005;73:
7317–23.
Nicholson TL, Brockmeier SL, Loving CL. Contribution of Borde-
tella bronchiseptica filamentous hemagglutinin and pertactin
to respiratory disease in Swine. Infect Immun 2009;77:2136.
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